文献速递介入腹部DSA

采用氰基丙烯酸正丁酯胶进行门静脉栓塞优于其他材料:系统评价与Meta分析

Portal vein embolization with N-butyl cyanoacrylate glue is superior to other materials: a systematic review and meta-analysis.
PubMed 文献 · Eur Radiol · 2021-01-26

该系统评价与Meta分析纳入51篇文献共2896例患者,比较不同门静脉栓塞材料诱导未来肝残余增生的效果;NBCA组未来肝残余增长率49.1%±29.7优于微颗粒组42.2%±40(p=0.037),且局部数据显示NBCA手术时间、透视时间、辐射剂量和材料成本均更低。

要点

  • NBCA栓塞后未来肝残余增长率49.1%±29.7,优于微颗粒的42.2%±40(p=0.037)。
  • NBCA与微颗粒主要并发症率无显著差异:NBCA 4%(24/681) vs 微颗粒5%(25/494)(p>0.05)。
  • 局部数据中NBCA较微颗粒缩短手术时间(215 vs 348分钟)和透视时间(43 vs 96分钟)(p<0.001)。

核心结论

  • 结合未来肝残余增生、手术时间、辐射暴露和成本,NBCA行门静脉栓塞似乎是最佳选择。

研究设计与样本

  • 系统评价与Meta分析,检索Pubmed、Embase和Cochrane 1998年至2019年关于门静脉栓塞材料的文献,纳入51篇论文共2896例患者,年龄61.0±4.0岁,男性65%。
  • 采用随机效应Meta分析比较两种最常用材料的未来肝残余增长;另使用本地数据(n=52)比较NBCA与微颗粒的成本、辐射剂量和手术时间。

诊断标准与关键数值

  • NBCA组未来肝残余增长49.1%±29.7,微颗粒组42.2%±40(p=0.037)。
  • NBCA组增长成功率95.3%,微颗粒组90.7%(p<0.001)。
  • 主要并发症率NBCA 4%(24/681) vs 微颗粒5%(25/494)(p>0.05),无显著差异。
  • 本地数据中NBCA组(n=41) vs 微颗粒组(n=11):手术时间215 vs 348分钟、透视时间43 vs 96分钟(p<0.001),辐射剂量573 vs 1287 Gycm2(p<0.01),成本€816 vs €4233(p<0.0001)。

临床应用与阅片要点

  • 原文结论认为NBCA似乎是门静脉栓塞的最佳选择,综合了未来肝残余增生、手术时间、辐射暴露和成本。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: It remains uncertain which embolization material is best for portal vein embolization (PVE). We investigated the various materials for effectiveness in inducing future liver remnant (FLR) hypertrophy, technical and growth success rates, and complication and resection rates.

METHODS: A systematic review from 1998 to 2019 on embolization materials for PVE was performed on Pubmed, Embase, and Cochrane. FLR growth between the two most commonly used materials was compared in a random effects meta-analysis. In a separate analysis using local data (n = 52), n-butyl cyanoacrylate (NBCA) was compared with microparticles regarding costs, radiation dose, and procedure time.

RESULTS: In total, 2896 patients, 61.0 ± 4.0 years of age and 65% male, from 51 papers were included in the analysis. In 61% of the patients, either NBCA or microparticles were used for embolization. The remaining were treated with ethanol, gelfoam, or sclerosing agents. The FLR growth with NBCA was 49.1% ± 29.7 compared to 42.2% ± 40 with microparticles (p = 0.037). The growth success rate with NBCA vs microparticles was 95.3% vs 90.7% respectively (p < 0.001). There were no differences in major complications between NBCA and microparticles. In the local analysis, NBCA (n = 41) entailed shorter procedure time and reduced fluoroscopy time (p < 0.001), lower radiation exposure (p < 0.01), and lower material costs (p < 0.0001) than microparticles (n = 11).

CONCLUSION: PVE with NBCA seems to be the best choice when combining growth of the FLR, procedure time, radiation exposure, and costs.

KEY POINTS: • The meta-analysis shows that n-butyl cyanoacrylate (NBCA) is superior to microparticles regarding hypertrophy of the future liver remnant, 49.1% ± 29.7 vs 42.2% ± 40.0 (p = 0.037). • There is no significant difference in major complication rates for portal vein embolization using NBCA, 4% (24/681), compared with microparticles, 5% (25/494) (p > 0.05). • Local data shows a shorter procedure time, 215 vs 348 mins from arrival to departure at the interventional radiology unit, and fluoroscopy time, 43 vs 96 mins (p < 0.001), lower radiation dosage, 573 vs 1287 Gycm2 (p < 0.01), and costs, €816 vs €4233 (p < 0.0001) for NBCA compared to microparticles.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Ali A, Ahle M, Björnsson B, et al. Portal vein embolization with N-butyl cyanoacrylate glue is superior to other materials: a systematic review and meta-analysis. Eur Radiol. 2021. PMID: 33501598. doi:10.1007/s00330-020-07685-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。